secwatch.observer — SEC 8-K summary
======================================

Issuer:     Syndax Pharmaceuticals Inc (SNDX)
CIK:        0001395937
Form:       8-K
Filed at:   2022-02-24T23:59:59+00:00
Accession:  0001564590-22-006493
Event type: leadership
Sentiment:  neutral
Materiality: 0.35
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Director Fabrice Egros resigns from Syndax board; Dennis Podlesak joins Audit Committee
--------------------------------------------------------------------------------

- Fabrice Egros resigned from Syndax board effective Feb 23, 2022 due to expanded role at Lupin Limited.
- Resignation not due to any disagreement with the company on operations, policies, or practices.
- Board appointed Dennis G. Podlesak to the Audit Committee following Egros' departure.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1395937/000156459022006493/0001564590-22-006493-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1395937/000156459022006493/sndx-8k_20220222.htm
  HTML page:      https://secwatch.observer/filing/0001564590-22-006493

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer